Abstract: A system, apparatus, and method for treating a tissue site with reduced pressure includes a connector having a connector body. The connector body includes a cavity and a cavity aperture. The connector also includes a conduit port fluidly coupling a conduit to the cavity. The connector further includes a base adjacent the cavity aperture that is configured to be positioned adjacent a drape. The cavity is configured to be fluidly coupled to a manifold through an aperture of the drape. The connector also includes a sensing probe having a proximal end configured to be fluidly coupled to the conduit and a distal end extending to the cavity aperture. The distal end is configured to be positioned adjacent to and in fluid communication with a manifold.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: Dressings, systems, and methods are disclosed that, in some embodiments, relate to treating a tissue site. In one embodiment, a dressing may include a manifold, a retention pouch, a sealing member, and a conduit interface. The manifold may be adapted to distribute reduced pressure to the tissue site, and the retention pouch may be adapted to retain and manage fluid extracted from the tissue site. The sealing member may cover the retention pouch and the manifold to provide a sealed space with the tissue site. The conduit interface may be in fluid communication with the sealed space and an exterior surface of the sealing member. The dressing may be utilized with a therapy device operable to control reduced pressure in the dressing and fluid flow over the sealing member.

Abstract: Systems, devices, and methods of the present disclosure assist with management of tubes and hoses during surgical procedures. The systems, devices, and methods provide for the proper opening and closing of tubes to facilitate performance of steps in a surgical procedure.

Abstract: Inline storage pouches and systems for receiving and retaining body fluids from an animal are presented. The inline storage pouch include a flexible pouch body has an interior portion with a fluid storage material disposed within the interior portion. In addition to receiving body fluids, the inline storage pouch may fluidly couple a pressure sensing conduit between a first port and a second port using a first bypass conduit. The first port may be a patient-port interface. The second port may be a device-port interface. Multiple sensors and bypass conduits may be included and associated with a microprocessor that is configured to locate blockages or determine when the inline storage pouch is full. Another inline storage pouch has two chambers and receives and discharges fluids from a pouch connector. Other pouches, systems, and methods are presented herein.

Abstract: Wound dressings, systems, and methods are presented for treating a wound on a patient's limb, such as a venous leg ulcer. The dressings, systems, and methods involve creating airflow within the dressing to vaporize and remove liquid. The airflow may begin when the dressing becomes saturated. The dressings may be used to provide compression and reduced pressure to the wound. Other systems, methods, and dressings are presented herein.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: Wounds dressings, systems, and methods are presented that involve using a patient's body heat to enhance liquid removal from the wound dressing through a high-moisture-vapor-transmission-rate drape. Additional heat sources or devices, such as nano-antennas or electrical heating elements, may be added or used separately to enhance the removal liquid from the wound dressing. Other dressings, systems, and methods are presented herein.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: Fluid supply systems and methods for therapeutic fluid delivery systems, including those used for negative pressure wound therapy (NPWT) systems and methods.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: A device and method for transporting or repositioning a patient. The device comprises an air mover; a multi-layered body comprising a layer that is permeable to fluids, an layer comprising a spacer material, with which the air mover is in fluid communication, and a layer having a tensile strength sufficient to support the weight of a patient being lifted by the patient transport device. The device further comprises a plurality of coupling members coupled to the multi-layered body. In certain embodiments, the device comprises a further layer comprising a fluid-absorbent material.

Abstract: The present invention generally relates to devices and systems that utilize an inflatable bladder for generating, cutting, capturing, and/or transplanting one or more skin blisters. In some aspects, methods and devices in accordance with the present teachings can enable the harvesting of skin grafts from an increased variety of potential donor sites, such as areas of the body having uneven surfaces or a smaller radius of curvature (e.g., the arm) or large area donor sites where the creation of a vacuum may require a high power negative pressure source. In various aspects, systems, devices, and methods in accordance with the present teachings can also enable the efficient transplant of the grafts directly from the skin graft harvester to the recipient site without the transfer of the grafts generated by the harvester to another substrate prior to transplantation.

Abstract: Methods, devices and systems are disclosed for generating and harvesting skin grafts having improved properties and for ensuring efficient and consistent blister formation and/or reducing patient harm and discomfort. In one aspect, the invention infuses a fluid into skin tissue at the donor site to enhance blister formation. The fluid infusion can occur before or after application of negative pressure—or can be cyclically applied before or after repeated applications of negative pressure.

Abstract: Skin graft harvesting systems and methods are disclosed that utilize sensors to automate the harvesting of skin grafts or assist a user in deciding when the skin graft is ready to be harvested. Such systems and methods can reduce the burden of visual observation and ensure greater reliability and consistency of the grafts. The invention is particularly useful with harvesters that rely upon suction and/or heating to raise a plurality of small or “micro” blisters simultaneously.

Abstract: Provided are systems and methods for delivery of fluid to a wound therapy dressing. In exemplary embodiments, a pressure source provides negative pressure to a wound dressing and a biasing mechanism provides positive pressure to a fluid reservoir.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

Abstract: The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.